Epigenetic regulators of programmed death-ligand 1 expression in human cancers
Autor: | Surender Kumar Sharawat, Sachin Kumar |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Untranslated region B7-H1 Antigen Epigenesis Genetic Histones 03 medical and health sciences Neoplasms Physiology (medical) microRNA medicine Humans Gene silencing Epigenetics Transcription factor Messenger RNA biology Biochemistry (medical) Public Health Environmental and Occupational Health Cancer General Medicine DNA Methylation medicine.disease MicroRNAs 030104 developmental biology Histone biology.protein Cancer research |
Zdroj: | Translational Research. 202:129-145 |
ISSN: | 1931-5244 |
DOI: | 10.1016/j.trsl.2018.05.011 |
Popis: | The programmed cell death protein 1-programmed death-ligand 1 (PD-L1) axis has been successfully targeted in clinics and the use of immune check-point inhibitors have shown durable antitumor response in untreated or heavily treated advanced stage cancer. PD-L1 upregulation has been found to correlate with poor prognosis in multiple cancer types and expression of PD-L1 in intratumoral compartment has been suggested to influence immune response and act as a key determinant of checkpoint immunotherapy efficacy. Hence it becomes critical to understand the regulation of PD-L1 expression in cancer. Role of oncogenic signaling pathways and transcription factors such as PI3K-AKT, MEK-ERK, JAK-STAT, MYC, HIF-1α, AP-1 and NF-κB is well established in inducing PD-L1 expression. Even the structural variations resulting in the truncation of the 3' untranslated region (UTR) of PD-L1 has been shown to upregulate PD-L1 expression in multiple cancer types. Since microRNAs carry out post-transcriptional gene silencing by binding to the 3' UTR of its target messenger RNA, truncation of PD-L1 3' UTR can result in alleviation of PD-L1 suppression mediated by microRNA, leading to its overexpression. Other epigenetic modifications, such as promoter DNA methylation and histone modifications can also play crucial role in regulating PD-L1 expression. Here, we review recent findings and evidence on epigenetic mechanisms that regulate PD-L1 expression and the biological and clinical implications of such regulation in cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |